The relationship between HLA-G and viral loads in non-responder HCV-infected patients after combined therapy with IFN-α2α and ribavirin

Human Immunology

Volumn 76, Issue 2-3, 2015, Pages 181-186

  Khorrami, Samaneh ^a   Mohammadpour, Hemn ^b   Shahzamani, Kiana ^a   Zarif, Mahin Nikougoftar ^c   Sharifi, Amir Hoshang ^a   Merat, Shahin ^a   Poustchi, Hossein ^a  

^a TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b TARBIAT MODARES UNIVERSITY   (Iran)

^c HIGH INSTITUTE FOR RESEARCH AND EDUCATION IN TRANSFUSION MEDICINE   (Iran)

Author keywords

HLA G; IFN 2 ; IL 10; Responder and non responder patients; Ribavirin

Indexed keywords

HLA G ANTIGEN; INTERLEUKIN 10; PEGINTERFERON ALPHA2A; RIBAVIRIN; ALPHA INTERFERON; ANTIVIRUS AGENT;

ADULT; AGED; ANTIGEN EXPRESSION; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GENOTYPE; HEPATITIS C; HEPATITIS C VIRUS SUBTYPE 1A; HUMAN; MALE; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; VIRUS LOAD; ANTIVIRAL RESISTANCE; COMPARATIVE STUDY; DRUG EFFECTS; GENE EXPRESSION REGULATION; GENETICS; HEPACIVIRUS; IMMUNOTHERAPY; METABOLISM; MIDDLE AGED; MULTIMODALITY CANCER THERAPY; PHYSIOLOGY; VERY ELDERLY; YOUNG ADULT;

ADULT; AGED; AGED, 80 AND OVER; ANTIVIRAL AGENTS; COMBINED MODALITY THERAPY; DRUG RESISTANCE, VIRAL; FEMALE; GENE EXPRESSION REGULATION; HEPACIVIRUS; HEPATITIS C; HLA-G ANTIGENS; HUMANS; IMMUNOTHERAPY; INTERFERON-ALPHA; INTERLEUKIN-10; MALE; MIDDLE AGED; RIBAVIRIN; VIRAL LOAD; YOUNG ADULT;

EID: 84924029387     PISSN: 01988859     EISSN: 18791166     Source Type: Journal    
DOI: 10.1016/j.humimm.2014.12.012     Document Type: Article

References (22)

1. Pawlotsky J.-M. Pathophysiology of hepatitis C virus infection and related liver disease. Trends Microbiol 2004, 12:96.
2. Merat S., Rezvan H., Nouraie M., Jafari E., Abolghasemi H., Radmard A.R., et al. Seroprevalence of hepatitis C virus: the first population-based study from Iran. Int J Infect Dis 2010, 14(Supplement 3):e113.
3. Alavian S.M., Ahmadzad-Asl M., Lankarani K.B., Shahbabaie M.A., Bahrami Ahmadi A., Kabir A. Hepatitis C infection in the general population of Iran: a systematic review. Hepat Mon 2009, 9:211.
4. Yoneda S., Umemura T., Katsuyama Y., Kamijo A., Joshita S., Komatsu M., et al. Association of serum cytokine levels with treatment response to pegylated interferon and ribavirin therapy in genotype 1 chronic hepatitis C patients. J Infect Dis 2011, 203:1087.
5. Manns M.P., McHutchison J.G., Gordon S.C., Rustgi V.K., Shiffman M., Reindollar R., et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001, 358:958.
6. Fried M.W., Shiffman M.L., Reddy K.R., Smith C., Marinos G., Gonçales F.L., et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002, 347:975.
7. Bataller R., Brenner D.A. Liver fibrosis. J Clin Invest 2005, 115:209.
8. Amiot L., Vu N., Rauch M., L'Helgoualc'h A., Chalmel F., Gascan H., et al. Expression of HLA-G by mast cells is associated with hepatitis C virus-induced liver fibrosis. J hepatol 2014, 60(2):245-252.
9. González Ã., Rebmann V., LeMaoult J., Horn P.A., Carosella E.D., Alegre E. The immunosuppressive molecule HLA-G and its clinical implications. Crit Rev Clin Lab Sci 2012, 49:63.
10. Schulte D., Vogel M., Langhans B., Krämer B., Körner C., Nischalke H.D., et al. The HLA-ER/HLA-ER genotype affects the natural course of hepatitis C virus (HCV) infection and is associated with HLA-E-Restricted recognition of an HCV-Derived peptide by interferon-γ-secreting human CD8+ T cells. J Infect Dis 2009, 200:1397.
11. Knodell R.G., Ishak K.G., Black W.C., Chen T.S., Craig R., Kaplowitz N., et al. Formulation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis. Hepatology 1981, 1:431.
12. Bassat H.E., Ali L.A., Alm El-Din R.A., Hasby E., Shahbah A. Serum level of interleukin-10 with its gene polymorphism can be predictors of response to treatment in Egyptian patients with chronic hepatitis C virus. Egypt J Med Hum Gen 2013.
13. Oleksyk T., Thio C., Truelove A., Goedert J., Donfield S., Kirk G., et al. Single nucleotide polymorphisms and haplotypes in the IL10 region associated with HCV clearance. Genes Immun 2005, 6:347.
14. McGeachy M.J., Bak-Jensen K.S., Chen Y., Tato C.M., Blumenschein W., McClanahan T., et al. TGF-β and IL-6 drive the production of IL-17 and IL-10 by T cells and restrain TH-17 cell-mediated pathology. Nat Immunol 2007, 8:1390.
15. Weng P-J, Fu Y-M, Ding S-X, Xu D-P, Lin A., Yan W-H. Elevation of plasma soluble human leukocyte antigen-G in patients with chronic hepatitis C virus infection. Hum Immunol 2011, 72:406.
16. Han Q., Li N., Zhu Q., Li Z., Zhang G., Chen J., et al. Association of serum soluble human leukocyte antigen-G levels with chronic hepatitis B virus infection. Clin Exp Med 2012, 1.
17. Wang Y., Ye Z., Meng X.-Q., Zheng S.-S. Expression of HLA-G in patients with hepatocellular carcinoma. Hepatobiliary Pancreat Dis Int 2011, 10:158.
18. Amodio G., Gregori S. Distinctive immunological functions of HLA-G. Histocompatibility 2012, InTech, Rijeka. 10.5772/35248.
19. Grimbaldeston M.A., Nakae S., Kalesnikoff J., Tsai M., Galli S.J. Mast cell-derived interleukin 10 limits skin pathology in contact dermatitis and chronic irradiation with ultraviolet B. Nat Immunol 2007, 8:1095.
20. Vidal-Castiñeira J.R., López-Vázquez A., Alonso-Arias R., Moro-García M.A., Martinez-Camblor P., Melón S., et al. A predictive model of treatment outcome in patients with chronic HCV infection using IL28B and PD-1 genotyping. J Hepatol 2012, 56:1230.
21. Gobin S.J.P., Keijsers V., Van Zutphen M., Van Den Elsen P.J. The role of enhancer A in the locus-specific transactivation of classical and nonclassical HLA class I genes by nuclear factor κB. J Immunol 1998, 161:2276.
22. Carosella E., Gregori S., Rouas-Freiss N., LeMaoult J., Menier C., Favier B. The role of HLA-G in immunity and hematopoiesis. Cell Mol Life Sci 2011, 68:353.